Sun Pharma's IL-23 inhibitor tildrakizumab gains a psoriatic arthritis indication; the announcement cited no phase 3 efficacy figures.
|Articles|January 13, 2023
The Corporate Reputation of Pharma Survey Released
In its ninth year, the survey includes the opinions of over 240 US-based patient groups on the performance of the pharmaceutical industry in 2021.
Advertisement
The "The Corporate Reputation of Pharma in 2021 - The Patient Perspective - USA Edition - The Views of 240 USA Patient Groups" report has been added to ResearchAndMarkets.com's offering.
The 240 US patient groups responding to the 2021 survey rated the pharma industry more favorably for corporate reputation than their predecessors in previous years. 67% of 2021's respondent patient groups stated that the industry had an "Excellent" or "Good" corporate reputation, against 57% saying the same in 2020.
The positivity of 2021's respondent patient groups appears to be largely driven by the pharma industry's response to the Covid-19 pandemic–specifically, the success some US companies have had at developing vaccines and treatments. In total, 81% of 2021's respondent patient groups stated that pharma was "Very effective" or "Effective" at providing support to patients during the pandemic, the same percentage as in 2020.
Continue reading this story
Advertisement
Related to this article
Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.
Shionogi’s Dr. Draica on why mild COVID-19 still matters, how XOCOVA blocks replication before symptoms, and why prevention beats treatment.
Earlier pediatric planning, innovative trial design, and closer collaboration among regulators, industry, and families are needed to close the persistent gap between the evidence available for adult and pediatric treatments.
BioMarin licenses long-acting Fabry enzyme replacement therapy HM15421/GC1134A, while Ferring agrees to acquire fertility biotech Gameto.
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Shionogi’s Dr. Draica on why mild COVID-19 can worsen chronic conditions for up to a year — and why prevention matters more than hospitalization data suggests.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Ilumya for Adults With Active Psoriatic Arthritis
2
Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial
3
Closing the Pediatric Evidence Gap
4
Post-Exposure Prophylaxis Is the Missing Piece: Q&A with Florin Draica
5